Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a
 and ribavirin can result in higher cure rates in patients who previously failed therapy and
 may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.
Inclusion Criteria:

 -  Subjects chronically infected with HCV genotype 1

 -  Non-responder to prior therapy with peginterferon alfa and ribavirin

 -  HCV RNA viral load of 100,00 IU/mL

 -  Results of a liver biopsy ≤ 24 months prior to randomization consistent with chronic
 HCV infection; for compensated cirrhotics can be any time prior to randomization
 (compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study
 population)

 -  Ultrasound, CT scan or MRI results 12 months prior to randomization that do not
 demonstrate hepatocellular carcinoma

 -  Body Mass Index (BMI) of 18 to 35 kg/m2

 Exclusion Criteria:

 -  Positive for Hepatitis B infection (HBsAg) or HIV-1/HIV-2 antibody at screening

 -  Evidence of medical condition associated with chronic liver disease other than HCV

 -  Evidence of decompensated cirrhosis based on radiologic criteria or biopsy